Related Experiment Video

Updated: Aug 6, 2026

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
08:29

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Published on: May 14, 2018

The interferon-induced GTPase, mGBP-2, confers resistance to paclitaxel-induced cytotoxicity without inhibiting

S Balasubramanian1, S Nada, D Vestal

  • 1Department of Biological Sciences, University of Toledo, 2801 West Bancroft St., Toledo, OH 43606, USA.

Cellular and Molecular Biology (Noisy-Le-Grand, France)
|August 18, 2006
PubMed

Insights

Interferon-induced Guanylate Binding Protein 2 (mGBP-2) enhances cell survival against paclitaxel, a cancer therapy drug. This finding reveals a new role for interferon-stimulated genes in drug resistance.

Area of Science:

  • Cellular and Molecular Biology
  • Immunology
  • Cancer Biology

Background:

  • Interferon (IFN) exposure induces diverse cellular alterations, often mediated by gene regulation.
  • The Guanylate Binding Protein (GBP) family, a group of GTPases, is induced by both type I and type II IFNs.
  • The specific functions of many IFN-induced genes remain incompletely understood.

Purpose of the Study:

  • To investigate the functional role of a specific murine Guanylate Binding Protein, mGBP-2, in cellular response to therapeutic agents.
  • To determine if mGBP-2 expression influences cellular sensitivity to paclitaxel, a microtubule-stabilizing chemotherapy drug.

Main Methods:

  • NIH 3T3 cells were engineered to express murine GBP-2 (mGBP-2).
  • Cells were treated with varying concentrations of paclitaxel.
  • Cellular morphology (rounding, substrate detachment), cytotoxicity, multinucleation, and apoptosis were assessed in mGBP-2-expressing cells versus control cells.

Main Results:

  • mGBP-2 expression conferred significant resistance to paclitaxel-induced cytotoxicity across a range of drug concentrations (0.005 to 15 microM).
  • Paclitaxel-treated cells expressing mGBP-2 exhibited reduced cellular rounding and substrate detachment compared to control cells.
  • While mGBP-2 did not prevent the formation of multinucleate cells, it decreased the progression of these cells towards apoptosis.

Conclusions:

  • Murine GBP-2 (mGBP-2) confers resistance to paclitaxel, a microtubule-targeting cancer therapeutic.
  • mGBP-2 influences cellular responses to paclitaxel by mitigating cytotoxicity and altering cell fate pathways.
  • These findings highlight a potential role for interferon-stimulated genes, like mGBP-2, in modulating cancer therapy efficacy.

More Related Videos

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...